Title :

Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration.

Author(s) :

Frontzek, F. [Auteur]
University Hospital Münster - Universitaetsklinikum Muenster [Germany] [UKM]
Renaud, L. [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Dührsen, U. [Auteur]
University Hospital Essen [AöR]
Poeschel, V. [Auteur]

Bernard, S. [Auteur]
Chartier, L. [Auteur]
Ketterer, N. [Auteur]
Récher, C. [Auteur]
Fitoussi, O. [Auteur]
Held, G. [Auteur]
Casasnovas, O. [Auteur]
Haioun, C. [Auteur]
Mounier, N. [Auteur]
Tilly, H. [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Le Gouill, S. [Auteur]
Karsten, I. E. [Auteur]
Duns, G. [Auteur]
Steidl, C. [Auteur]
Scott, D. W. [Auteur]
Klapper, W. [Auteur]
Rosenwald, A. [Auteur]
Ott, G. [Auteur]
Molina, T. [Auteur]
Lenz, G. [Auteur]
Ziepert, M. [Auteur]
Leipzig University / Universität Leipzig
Altmann, B. [Auteur]
Leipzig University / Universität Leipzig
Thieblemont, C. [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Schmitz, N. [Auteur]
University Hospital Münster - Universitaetsklinikum Muenster [Germany] [UKM]

Journal title :

Leukemia

Abbreviated title :

Leukemia

Publisher :

Nature

Publication date :

2024-08-16

ISSN :

1476-5551

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Progression or relapse in the central nervous system (CNS) remains a rare but mostly fatal event for patients with diffuse large B-cell lymphoma (DLBCL). In a retrospective analysis of 5189 patients treated within 19 ...
Show more >Progression or relapse in the central nervous system (CNS) remains a rare but mostly fatal event for patients with diffuse large B-cell lymphoma (DLBCL). In a retrospective analysis of 5189 patients treated within 19 prospective German and French phase 2/3 trials, we identified 159 patients experiencing a CNS event (relapse: 62%, progression: 38%). Intracerebral, meningeal, intraspinal, or combined involvement was reported in 44%, 31%, 3%, and 22% of patients, respectively. 62 of 155 evaluable patients (40%) showed concurrent systemic progression/ relapse. 82% of all CNS events occurred within two years after study inclusion or randomization. 87% of patients showed extranodal involvement outside the CNS. Patients generally had poor outcomes with a median overall survival (OS) of 3.4 months (95% CI 2.9–4.2) and a 2-year OS of 15% (10–22%). Outcomes did not differ depending on the site or time point of CNS events. Patients with isolated CNS events demonstrated significantly better OS (p = 0.023). Twenty-five patients were consolidated with autologous or allogeneic stem cell transplantation and achieved a 3-year OS of 36% (20–66%). This large study including more than 5000 DLBCL patients highlights the unmet medical need to improve the outcome of DLBCL patients suffering from CNS relapse.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Submission date :

2024-09-06T21:03:24Z
2024-09-18T08:38:46Z